- Evaluation of NBTXR3 for global registration in priority
head and neck cancer pathway proceeds with the first European
patient randomized in global phase III NANORAY-312 study; US and
Asia site activation expected in 2022
- Priority NBTXR3 plus anti-PD-1 combination program poised to
advance as the Company seeks to define registration pathway with
regulatory agencies based on initial data from ongoing phase I
immunotherapy study
- Operating runway extended into second quarter 2023 as a
result of enhancing operational efficiencies and optimizing capital
allocation for continued investment in priority development
pathways
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the
‘‘Company’’), a late-stage clinical biotechnology company
pioneering physics-based approaches to expand treatment
possibilities for patients with cancer, today provided a corporate
update highlighting key priorities and anticipated development
milestones for 2022.
“We believe 2021 provided strong validation of the broad
potential therapeutic benefit of NBTXR3 and the capabilities of the
Nanobiotix team,” said Laurent Levy, co-founder and chairman of the
executive board of Nanobiotix. “Not only did our single-agent and
combination development programs yield new data suggesting
radiotherapy-activated NBTXR3 may improve clinical outcomes for
patients with either local or systemic disease, but we were also
able to launch NANORAY-312, our global phase III registration study
in head and neck cancer. This momentum enabled us to move quickly
to begin 2022, with the first European patient randomized in our
phase III study and recruitment efforts well under way. In
parallel, in 2021 we strengthened our leadership team with the
appointment of both a new supervisory board Chairman and new Chief
Financial Officer; and added a new strategic partner to advance and
expand development of NBTXR3 in Asia. Moreover, we took measures to
increase operational efficiencies and optimize capital allocation,
effectively extending our operating runway while further
strengthening our priority development pathways. Our priorities for
the year remain focused on executing our ongoing studies, capturing
the opportunity to drive value by defining our registration
strategy in immunotherapy, and expanding the tumor-agnostic,
combination-agnostic profile of NBTXR3 through our strategic
collaborations.”
2022 Corporate
Priorities
The Nanobiotix mission is to improve treatment outcomes for
patients around the world by developing and commercializing
disruptive, nanophysics-based therapeutic solutions across multiple
major disease areas, beginning with cancer. In 2022, Nanobiotix
plans to continue to grow and strengthen its organizational
capabilities in order to deliver on the potential of its lead
product candidate, NBTXR3.
Key corporate priorities for the year are as follows:
- Focus Company-led development efforts on the execution of
NANORAY-312, a global, pivotal study seeking regulatory market
approval of NBTXR3 as a single-agent activated by radiation in
locally advanced head and neck squamous cell carcinoma (HNSCC; head
and neck cancer) and the advancement of a follow-on checkpoint
inhibitor combination strategy for patients naïve to anti-PD-1
treatment as well as patients with inadequate or no response to
prior anti-PD-1 treatment
- Advance the expansion of NBTXR3’s global pipeline through
existing collaborations and/or the addition of new collaborations
that can potentially contribute complementary development and/or
commercial capabilities
- Further align resources and capital allocation with strategic
priorities and enhance operating efficiencies
- Deepen operational expertise in key functional areas to support
continued company growth
- Continue to foster a company culture of innovation, integrity,
accountability, transparency, and inclusion
2022 Development Pipeline
Objectives
In 2022, the Nanobiotix development program will continue to
focus on: (i) Execution of Company-led priority pathways in HNSCC
and immunotherapy, and (ii) working with existing and future
collaborators to expand the development footprint for NBTXR3.
Key development objectives and expected milestones as
follows:
- Advance toward NBTXR3 global commercial registration through
NANORAY-312, evaluating the product candidate as a single-agent
activated by radiotherapy for high-risk elderly patients with
locally advanced HNSCC following preliminary survival data from
phase I dose expansion study (Study 102 Expansion) showing a
potential benefit for elderly patients with a worse prognosis.
Expected 2022 milestones include:
- Randomize First NANORAY-312 Patient in Europe – January 2022
(Achieved)
- Activate First NANORAY-312 US Site
- Activate First NANORAY-312 Asia Site (LianBio)
- Establish a planned path to registration for NBTXR3 in
combination with anti-PD-1 following initial data from the
Company’s ongoing phase I study (Study 1100) suggesting NBTXR3 may
prime immune response, enhance response rates in anti-PD-1 naïve
patients, and help overcome resistance to prior anti-PD-1 therapy
in non-responders. Expected 2022 milestones include:
- Establish Recommended Phase II Dose (RP2D) in all cohorts
- Present Updated Study 1100 Data
- Announce Development Next Steps Following Regulatory Agency
Feedback
- Expand evaluation of NBTXR3 safety and feasibility to
additional solid tumor indications and therapeutic combinations
outside of Company-led pathways through collaborators. Expected
2022 milestones include:
- Establish Recommended Phase II Dose (RP2D) in Pancreatic
Cancer
- Present Data from Phase I evaluation of NBTXR3 plus
chemoradiation in HNSCC
- Present Data from Phase I/II evaluation of NBTXR3 plus
chemoradiation in Rectal Cancer
2021 Year-End Cash
As of December 31, 2021, Nanobiotix estimates that it had
approximately €83.9 million in cash, cash equivalents, and
investments, compared to €119.2 million as of December 31, 2020.
Following comprehensive operational adjustments undertaken in the
second half of 2021, Nanobiotix has been able to extend its
operating runway and now expects that its cash, cash equivalents,
and investments as of December 31, 2021, excluding any future
potential milestones that may be received by the Company from
collaborations, will enable the Company to fund its current
operational plan into the second quarter of 2023. This estimate of
cash, cash equivalents and investments is preliminary and is based
on information currently available and may differ from the actual
cash balance to be included in the Company’s audited financial
statements.
Upcoming Investor Conferences in
January 2022
H.C. Wainwright Bioconnect Conference Date: January 10-13, 2022
Format: Corporate presentation Time: Presentation available for
registered attendees starting January 10, 2022 at 7:00 AM (EST) /
1:00 PM (CET)
Biotech Showcase™ 2022 Date: January 17-19, 2022 Format:
Corporate presentation and virtual one-on-one meetings with
investors Time: Presentation available for registered attendees
starting January 10, 2022 at 7:00 AM (EST) / 1:00 PM (CET)
An updated corporate overview presentation is available on the
Investors section of the Company’s website at
https://www.nanobiotix.com/stock-information and a webcast of the
H.C. Wainwright Bioconnect Conference will be archived in the
events section at https://www.nanobiotix.com/events.
2022 Financial Agenda
- March 30, 2022 – 2021 Full-Year Corporate and Financial
Update
- May 10, 2022 – First Quarter 2022 Corporate and Financial
Update
- June 17, 2022 – Annual General Meeting, Paris, France
- September 7, 2022 – 2022 Half-Year Corporate and Financial
Update
- November 9, 2022 – Third Quarter 2022 Corporate and Financial
Update
***
About NBTXR3
NBTXR3 is a novel, potentially first-in-class oncology product
composed of functionalized hafnium oxide nanoparticles that is
administered via one-time intratumoral injection and activated by
radiotherapy. The product candidate’s physical mechanism of action
(MoA) is designed to induce significant tumor cell death in the
injected tumor when activated by radiotherapy, subsequently
triggering adaptive immune response and long-term anti-cancer
memory. Given the physical MoA, Nanobiotix believes that NBTXR3
could be scalable across any solid tumor that can be treated with
radiotherapy and across any therapeutic combination, particularly
immune checkpoint inhibitors.
NBTXR3 is being evaluated in locally advanced head and neck
squamous cell carcinoma (HNSCC) as the primary development pathway.
The company-sponsored phase I dose escalation and dose expansion
study has produced favorable safety data and early signs of
efficacy. In February 2020, the United States Food and Drug
Administration granted regulatory Fast Track designation for the
investigation of NBTXR3 activated by radiation therapy, with or
without cetuximab, for the treatment of patients with locally
advanced HNSCC who are not eligible for platinum-based
chemotherapy.
Nanobiotix has also prioritized an Immuno-Oncology development
program—beginning with a Company sponsored phase I clinical study
evaluating NBTXR3 activated by radiotherapy in combination with
anti-PD-1 checkpoint inhibitors for patients with locoregional
recurrent or recurrent/metastatic HNSCC and lung or liver
metastases from any primary cancer eligible for anti-PD-1 therapy
either naïve or resistant to prior PD-1 (either primary or
secondary as per SITC criteria).
Given the Company’s focus areas, and balanced against the
scalable potential of NBTXR3, Nanobiotix has engaged in strategic
collaborations to expand development of the product candidate in
parallel with its priority development pathways. Pursuant to this
strategy, in 2019 Nanobiotix entered into a broad, comprehensive
clinical research collaboration with The University of Texas MD
Anderson Cancer Center to sponsor several phase I and phase II
studies to evaluate NBTXR3 across tumor types and therapeutic
combinations. In 2021, the Company entered into an additional
strategic collaboration agreement with LianBio to support its
global phase III study in Asia along with four future
registrational studies.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company
pioneering disruptive, physics-based therapeutic approaches to
revolutionize treatment outcomes for millions of patients;
supported by people committed to making a difference for humanity.
The company’s philosophy is rooted in the concept of pushing past
the boundaries of what is known to expand possibilities for human
life.
Incorporated in 2003, Nanobiotix is headquartered in Paris,
France. The company also has subsidiaries in Cambridge,
Massachusetts (United States), France, Spain, Germany and
Switzerland.
Nanobiotix has been listed on the regulated market of Euronext
in Paris since 2012 and on the Nasdaq Global Select Market in New
York City since December 2020.
Nanobiotix is the owner of more than 30 umbrella patents
associated with three (3) nanotechnology platforms with
applications in 1) oncology; 2) bioavailability and
biodistribution; and 3) disorders of the central nervous system.
The company's resources are primarily devoted to the development of
its lead product candidate– NBTXR3 —which is the product of its
proprietary oncology platform and has already achieved market
authorization in Europe for the treatment of patients with soft
tissue sarcoma under the brand name Hensify®.
For more information about Nanobiotix, visit us at
www.nanobiotix.com or follow us on LinkedIn and Twitter.
Disclaimer
This press release contains certain “forward-looking” statements
within the meaning of applicable securities laws, including the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by words such as “at this time,”
“anticipate,” “believe,” “expect,” “intend,” “on track,” “plan,”
“scheduled,” and “will,” or the negative of these and similar
expressions. These forward-looking statements, which are based on
our management’s current expectations and assumptions and on
information currently available to management, include statements
about the timing and progress of clinical trials, the timing of our
presentation of data, the results of our preclinical and clinical
studies and their potential implications. Such forward-looking
statements are made in light of information currently available to
us and based on assumptions that Nanobiotix considers to be
reasonable. However, these forward-looking statements are subject
to numerous risks and uncertainties, including with respect to the
risk that subsequent studies and ongoing or future clinical trials
may not generate favorable data notwithstanding positive early
clinical results and the risks associated with the evolving nature
of the duration and severity of the COVID-19 pandemic and
governmental and regulatory measures implemented in response to it.
Furthermore, many other important factors, including those
described in our Annual Report on Form 20-F filed with the U.S.
Securities and Exchange Commission (the SEC) on April 7, 2021 under
“Item 3.D. Risk Factors” and those set forth in the universal
registration document of Nanobiotix filed with the French Financial
Markets Authority (Autorité des Marchés Financiers – the AMF) on
April 7, 2021, each as updated in our Half-Year Financial Report
filed with the AMF and the SEC on September 8, 2021 (a copy of
which is available on www.nanobiotix.com), as well as other known
and unknown risks and uncertainties may adversely affect such
forward-looking statements and cause our actual results,
performance or achievements to be materially different from those
expressed or implied by the forward-looking statements. Except as
required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
2022 Development Outlook
Overview
STUDY
STATUS
ANTICIPATED 2022
MILESTONES
Company-Led Single-Agent
Pathway
Phase III Registration Study of NBTXR3
in Head and Neck Cancer
Nanobiotix Study NANORAY-312
First patient randomized in Europe
Expect site activation in US
Expect site activation in Asia
(LianBio)
Phase I Expansion Study of NBTXR3 in
Head and Neck Cancer
Nanobiotix Study 102 Expansion
Survival data presented at ASTRO 2021
Continued follow up of patients to assess
longer term safety and efficacy data
Post-Registrational Study of NBTXR3 in
Soft Tissue Sarcoma
Nanobiotix Study 401
In preparation
Preparation for study launch in EU
Company-led Checkpoint Inhibitor
Combination Pathway
Phase I Study of NBTXR3 in Combination
with Anti-PD-1 for Patients with Head and Neck Cancer, Lung
Metastasis and/or Liver Metastasis
Nanobiotix Study 1100
Updated results presented at ASTRO
2021
Contact initiated with regulatory agencies
regarding development plan in IO
Expect determination of RP2D for all
cohorts
Expect presentation of updated data
Expect announcement of development next
steps in IO following regulatory agency feedback
Collaborator-led Expansion Across
Indications and Therapeutic Combinations
Phase II Study of NBTXR3 in Combination
with Anti-PD-1 for Patients with Recurrent/Metastatic Head and Neck
Cancer with Limited PD-L1 Expression
MD Anderson Study 2020-0541
First patients enrolled in 2021
Active and recruiting
Updates to be provided as they are made
available by MD Anderson
Phase II Study of NBTXR3 in Combination
with Anti-PD-1/L1 for Patients with Inoperable Head and Neck Cancer
Amenable to Re-irradiation
MD Anderson Study 2020-0354
Active and recruiting
Updates to be provided as they are made
available by MD Anderson
Phase I Study of NBTXR3 in
Esophageal Cancer
MD Anderson Study 2020-0122
Active and recruiting
Updates to be provided as they are made
available by MD Anderson
Phase I Study of NBTXR3 in Pancreatic
Cancer
MD Anderson Study 2019-1001
Active and recruiting
First dose level completed
Final dose level enrolling
Expect determination of RP2D
Updates to be provided as they are made
available by MD Anderson
Phase I Study of NBTXR3 in Lung Cancer
Amenable to Re-irradiation
MD Anderson Study 2020-0123
Active and recruiting
Updates to be provided as they are made
available by MD Anderson
Phase I/II Study of PEP503 (NBTXR3)
with Radiotherapy in Combination with Concurrent Chemotherapy for
Patients with Head and Neck Cancer
Study PEP503-HN-1002
Concluded
Expect data presentation
Phase I/II Study of PEP503 with
Radiotherapy in Combination with Concurrent Chemotherapy for
Patients with Locally Advanced or Unresectable Rectal
Cancer
Study PEP503-RC-1001
Concluded
Expect data presentation
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220109005024/en/
Nanobiotix
Communications Department Brandon Owens VP,
Communications +1 (617) 852-4835 contact@nanobiotix.com Investor
Relations Department Kate McNeil SVP, Investor Relations +1
(609) 678-7388 investors@nanobiotix.com
Media Relations
FR – Ulysse Communication Pierre-Louis Germain + 33
(0) 6 64 79 97 51 plgermain@ulysse-communication.com US
– Porter Novelli Dan Childs +1 (781) 888-5106
Dan.childs@porternovelli.com
Nanobiotix (EU:NANO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Nanobiotix (EU:NANO)
Historical Stock Chart
From Dec 2023 to Dec 2024